← Back to Search

Aminopeptidase inhibitor

Tosedostat for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Research Sponsored by Chroma Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up protocol-mandated visits every 12 weeks
Awards & highlights

Study Summary

The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~protocol mandated visits every 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and protocol mandated visits every 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability of extended treatment with tosedostat
Secondary outcome measures
Efficacy of extended treatment with tosedostat

Side effects data

From 2017 Phase 2 trial • 12 Patients • NCT02452346
58%
Other - BNP increased
50%
Fatigue
50%
Electrocardiogram QT corrected interval prolonged
42%
Bruising
42%
Diarrhea
42%
Edema limbs
33%
Hypomagnesemia
25%
Alanine transferase increased
25%
Dyspnea
25%
Hypokalemia
25%
Platelet count decreased
25%
Urticaria
25%
Dizziness
25%
Dry skin
25%
Ejection fraction decreased
17%
Fall
17%
GGT increased
17%
Insomnia
17%
Neutrophil count decreased
17%
Pain in extremity
17%
Toothache
17%
Cough
17%
Febrile neutropenia
8%
Sore throat
8%
Sepsis
8%
Blurred vision
8%
Atrial fibrillation
8%
Creatinine increased
8%
Urinary incontinence
8%
Syncope
8%
Edema face
8%
Pulmonary hypertension
8%
Urinary tract infection
8%
Other - Muscle cramps
8%
Weight loss
8%
Fever
8%
Abdominal pain
8%
Alkaline phosphatase increased
8%
Allergic reaction
8%
Cardiac troponin I increased
8%
Confusion
8%
Constipation
8%
Delirium
8%
Hemorrhoids
8%
Hiccups
8%
Hypoxia
8%
INR increased
8%
Lethargy
8%
Other - Ferritin increased
8%
Other - Forgetfulness
8%
Other - left subconjunctival hemorrhage
8%
Other - Lip excoriation
8%
Other - Muscle spasm
8%
Other - Pneumonia
8%
Paresthesia, foot
8%
Pulmonary edema
8%
Rash pustular
8%
Anemia
8%
Aspartate aminotransferase increased
8%
Back pain
8%
Blood bilirubin increased
8%
Cognitive disturbance
8%
Depression
8%
Flank pain
8%
Fracture
8%
Gastroenteritis
8%
Hemorrhoidal hemorrhage
8%
Mucositis
8%
Nausea
8%
Neuralgia
8%
Non-cardiac chest pain
8%
Oral hemorrhage
8%
Other - Demand ischemia
8%
Epistaxis
8%
Dry mouth
8%
Vomiting
8%
Other - Decline in performance status
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Patients

Trial Design

1Treatment groups
Experimental Treatment
Group I: TosedostatExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tosedostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Chroma TherapeuticsLead Sponsor
9 Previous Clinical Trials
344 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
2010. "Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01180426.
All > Acute Myeloid Leukemia > Aml
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top